AstraZeneca plc (LON:AZN) has announced that PT027 has been recommended by FDA advisory committee as new rescue treatment for asthma. The Food and Drug Administration’s (FDA)..

Positive high-level results from the CAPItello-291 Phase III trial showed that AstraZeneca plc (LON:AZN) capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically..

AstraZeneca plc (LON:AZN) has announced that Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with..

AstraZeneca plc (LON:AZN) and Sanofi’s Beyfortus (nirsevimab) has been recommended for marketing authorisation in the European Union (EU) for the prevention of respiratory syncytial virus (RSV)..

AstraZeneca plc (LON:AZN) Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate..

Detailed results from the DELIVER Phase III trial showed AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure..

AstraZeneca plc (LON:AZN) supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review..

AstraZeneca plc (LON:AZN) has announced that positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician’s choice of treatment showed the..

AstraZeneca plc (LON:AZN) has completed the acquisition of TeneoTwo, Inc.i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low..

AstraZeneca plc (LON:AZN) and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant..

AstraZeneca PLC (LON:AZN) has announced the appointment of Michel Demaré as the Chair-designate of the Board. His appointment followed a robust succession planning process led by..

AstraZenec plc (LON:AZN) Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients..

AstraZeneca plc (LON:AZN) has announced an agreement to acquire TeneoTwo, Inc.i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and..

AstraZeneca plc (LON:AZN) Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-small cell lung cancer. Positive high-level results from..

AstraZeneca plc (LON:AZN) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of..

AstraZeneca plc (LON:AZN) Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative..

AstraZeneca plc (LON:AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US..

AstraZeneca PLC (LON:AZN) has announced its first quarter 2022 results. Revenue and EPS summary       Q1 2022 % Change     $m  Actual  CER1 ..